Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients.

Consider the origins of America’s cosmetic and supplement industry and the advertising practices that sustain it.

During or after conflict, a clinician might be required to provide evidence to an official investigatory body or court.

Marissa Chaet Brykman joins Ethics Talk to discuss her article, coauthored with Dr Virginia Streusand Goldman, Dr Nandakumara Sarma, Dr Hellen A. Oketch-Rabah, Deborah Biswas and Dr Gabriel I. Giancaspro: “What Should Clinicians Know About Dietary Supplement Quality?”

Dr Ilisa B. G. Bernstein joins Ethics Talk to discuss her article, coauthored with Karin L. Bolte: “Is My Patient Taking an Unsafe Dietary Supplement?”

Elizabeth Richardson joins Ethics Talk to discuss her article, coauthored Farzana Akkas and Dr Amy B. Cadwallader: “What Should Dietary Supplement Oversight Look Like in the US?”

Dr Alexander Ding joins Ethics Talk to discuss his article, coauthored with Dr Amy B. Cadwallader and other members of the AMA Council on Science and Public Health: “Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention?”

Jorie Braunold joins Ethics Talk to discuss her article: “How Long Have Supplements Promised to Make Us Slim, Sexy, and Virile?”

Weaknesses in regulatory approaches to negligent misrepresentation claims about dietary can have clinical and public health consequences.